IONS - Public offerings

- First independent launch underway following TRYNGOLZATM approval - - Second independent launch on track with donidalorsen PDUFA August 21, 2025 - - WAINUATM U.S. launch delivering accelerating sequential growth - - Ionis exceeds 2024 financial guidance and provides full year 2025 guidance - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2024. "With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company," said Brett P. Monia, Ph.D., chief executive of

WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the third quarter of 2024. "Today, we stand on the cusp of a new era for Ionis, with our first co-commercialization launch proceeding well with WAINUA, our first planned

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis has granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of its common stock at the public offering price per share, less underwriting discounts and commi

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock offered in the public offering on the same terms and conditions. Ionis intends to use the net proceeds from the offering to fund its independent commercial launches, late-stage clinical programs, earlier pipeline programs, and research and development activities, as well as for working capital and general corporate purposes. The offering is subject to market and other conditions,

 Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,000 referrals received to date that meet pre-qualifying eligibility criteria; topline results expected in the second half of 2024 Randomization in PRAX-562 Phase 2 EMBOLD study completed in pediatric patients with developmental and epileptic encephalopathies (DEEs), with topline results expected in the third quarter of 2024 Completed two underwritten public offerings in 2024; Cash and investments of $451

SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, which has an additional mandate to invest in public market opportunities. 5AM is pleased to announce the addition of two Venture Partners to the firm's investment team, and a Venture Advisor to the advisory team. Dr. Arthur Tzianabos has joined 5AM as a Venture Pa

CARLSBAD, Calif., Jan. 19, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced two appointments that strengthen its leadership team and further position it to become a leading, fully integrated biotechnology company. Joseph T. Baroldi will assume the role of executive vice president and chief business officer, effective Jan. 31, 2022. He will serve as a member of Ionis' executive leadership team and report to Brett P. Monia, Ph.D., Ionis' chief executive officer. In his role, Mr. Baroldi will provide strategic guidance for and lead Ionis' business development and alliance management activities. The company also appointed Eric P. Bastings, M.D., as vice president, d